Founded in 1998 in Ulanqab, Inner Mongolia, Furui has established its management headquarters in Beijing and expanded its footprint globally with subsidiaries in France, the United States, Germany, Spain, the United Kingdom, Italy, Singapore, and Hong Kong. The company was listed on the ChiNext Board of the Shenzhen Stock Exchange in 2010 under the ticker 300049.

As a leading player in liver disease prevention and treatment for over two decades, Furui remains committed to its mission: "Keep every family away from liver cancer". The company continues to advance scientific breakthroughs that benefit patients and support China's broader "Healthy China" initiative for liver cancer control.

Furui’s medical device subsidiary, Echosens, was founded in 2001. Its flagship product, FibroScan^®, is powered by proprietary VCTE™ and CAP™ technologies and is widely used in over 127 countries and regions. Endorsed as the "Best" recommendation in U.S. clinical guidelines and uniquely recommended by the World Health Organization in its category. As of 2024, more than 5,384 clinical studies reference FibroScan^®, and it is cited in over 218 authoritative guidelines and consensus documents. FibroScan® has become an indispensable diagnostic tool worldwide in the prevention and management of fatty liver disease, liver fibrosis, and liver cancer. Notably, FibroScan^® was included in the label of the world's first small-molecule drug for MASH (Metabolic dysfunction-associated steatohepatitis) in 2024.

Furui’s signature pharmaceutical product, the Compound Biejia Ruangan Tablet, when combined with antiviral therapy, has demonstrated significant efficacy in reducing liver cancer incidence. These findings were published in the top hepatology journal Journal of Hepatology, representing the most influential piece of evidence-based research for traditional Chinese medicine in this field to date.

The company is also ramping up its medical services business, implementing an integrated model of "screening, assessment, management, treatment, and insurance" under a value-based care framework. Furui is building a global consensus on liver fibrosis and laying the foundation for a specialized, managed healthcare group focused on liver health.